OncoSec Medical Incorporated · OTC:ONCSQ

OncoSec Medical — Investor Presentation (June 2021)

41 slides from OncoSec Medical's investor presentation, June 2021

  1. Slide 1: Powerful, Tumor-agnostic Immunotherapy Treatment

    Powerful, Tumor-agnostic Immunotherapy Treatment ONCOSEC’S PLATFORM TO ATTACK VISCERAL, CUTANEOUS AND SUBCUTANEOUS TUMORS NASDAQ: ONCS JUNE 2021

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS To the extent statements contained in the following product candidates; (vii) our ability to attract and presentations are not descriptions of historical retain key scientific or management personnel; (viii) facts regarding OncoSec Medical Incorporated, they the anticipate

  3. Slide 3: Investment Highlights

    Ticker: NASDAQ: ONCS Investment Highlights Market Cap (as of 6/17/21): ~$133M Stock Price (as of 6/17/21): $3.48 • Biotechnology company focused on intratumoral (IT) delivery of DNA-based immunotherapies as monotherapy and in combination regimes • Developing treatments for solid tumor cancer indicat

  4. Slide 4: The Promise of Immunotherapy Has Yet to Be Fully Realized

    How Checkpoint Inhibitors Work The Promise of Molecular switches known as Immunotherapy Has 1 checkpoints normally prevent T- cells from attacking healthy Yet to Be Fully Realized tissue When these checkpoints, such 2 as PD-1 and PD-L1, are hijacked by cancer cells, the immune system’s T-cell respon

  5. Slide 5: Checkpoint Non-response in 60-90% of Cases

    Checkpoint Powerful drugs (like KEYTRUDA®) have been Non-response highly successful for some patients, but not the majority in 60-90% 90% of cancers are solid tumors. Of these: of Cases % OF CHECKPOINT TUMOR TYPE NON-RESPONDERS MELANOMA ˜60-80% ~30% ~70% Hot Tumors Cold Tumors TRIPLE NEGATIVE BREAST

  6. Slide 6: TAVO is Capable of Reversing Resistance to Checkpoint Therapies

    TAVO (plasmid-based interleukin-12) is administered TAVO™ is Capable of locally at the tumor site using OncoSec’s electroporation gene delivery system. TAVO is designed to induce local Reversing Resistance expression of IL-12, turning “cold” tumors “hot” and enabling checkpoint therapies to be effec

  7. Slide 7: Making IL-12 More Safe: Systemic vs Local Delivery

    MAKING IL-12 MORE SAFE: SYSTEMIC VS LOCAL DELIVERY IV cytokine Conjugates IT rProtein Nanoparticles Plasmid electroporation Systemic Local rIL2-IT Plasmid IL-12 EP IL-12 • Transient exposure • Cells makes IL-12 • Regression of treated lesions • 1 week exposure / tx • No systemic effects • Systemic e

  8. Slide 8: IL-12 Is a Key Mediator of Communication Between Innate and Adaptive Cells

    IL-12 IS A KEY MEDIATOR OF COMMUNICATION BETWEEN DC/MACROPHAGES (INNATE) & EFFECTOR T CELLS AND NK CELLS (ADAPTIVE) Lasek W, et al, Cancer Immunol Immunother 2014

  9. Slide 9: Benefits of Electro Gene Transfer System

    Benefits of Electro Gene Transfer System A non-invasive, Rapid Transfection Versatile non-chemical, Wide array of molecules More rapid than can be transfected, and non-toxic method traditional chemical or can be applied to a broad biologic cell transfection selection of cell types that is easy techn

  10. Slide 10: Seamless Delivery Of Plasmid IL-12

    Seamless Generator Delivery Of • Fixed electrical field intensity • Momentary electrical pulses Plasmid IL-12 (100 µsec duration and 300 millisecond interval) + Energy • Pulses activated by foot switch • 16 lbs. 12.5” w x 5.5” h x 13” d Step 3: Electroporation Electrical pulses, activated by a foot

  11. Slide 11: Gene Electro Transfer of Immunotherapy: An Intratumoral IL-12 Factory

    Gene Electro Transfer of Immunotherapy: An Intratumoral IL-12 Facto The IL-12 Factory DNA plasmid IL-12 is injected into the IL-12/IFN𝛾𝛾 Feed Forward Loop tumor, followed by Tumors express IL-12 a 3 sec. pulse of stimulating NK and T energy cells to make IFN-𝛾𝛾, which then feeds Tumor cells…

  12. Slide 12: TAVO: A Tumor Agnostic Platform with Single Agent Activity

    5 TAVO: A Tumor Agnostic CLINICAL/ IMMUNOLOGICAL SIGNAL IN FIVE TUMOR TYPES Platform with Single Agent Activity TAVO + PEMBRO COMBINATION TAVO SINGLE AGENT SPONSORED TRIALS INVESTIGATOR-SPONSORED TRIALS Metastatic Melanoma Metastatic TNBC U.S. Orphan Accelerated Metastatic Metastatic Fast Track Appr

  13. Slide 13: Clinical Pipeline is Diversified with Several Growth Opportunities

    Clinical Pipeline is Diversified with Several Growth Opportunities REGIMEN TRIAL INDICATION N PARTNER PHASE 1 PHASE 2 PIVOTAL Checkpoint TAVO + KEYNOTE-695 Resistant Metastatic ~100 pembrolizumab Melanoma Triple Negative TAVO + KEYNOTE-890 Breast Cancer ~65 pembrolizumab (TNBC) TAVO™ TAVO + OMS-131

  14. Slide 14: Advanced Melanoma Overview

    Advanced Melanoma Overview Nearly all patients progress after 70-80% of anti-PD-1/PD-L1 therapy initial responders 40-45% fail relapse Treatment options are extremely checkpoint (acquired inhibitors ~15,000 Patients resistance)2 limited once a patient fails (primary receiving PD-1 checkpoint inhibit

  15. Slide 15: FDA Fast Track KEYNOTE-695

    FDA Fast Track KEYNOTE-695 Ongoing pivotal trial in PD-1 checkpoint resistant metastatic melanoma provides a pathway towards accelerated approval GRANTED FAST TRACK AND ORPHAN DRUG DESIGNATIONS Fast-track makes Program for Must meet TAVO™ eligible for patients with no RECIST (tumor accelerated FDA a

  16. Slide 16: KEYNOTE-695 Trial Design and Eligibility

    Up To Number Of 30 Sites PATIENTS TO BE TREATED 100 Canada Italy United States Australia DEFINITIVE CLINICAL PROGRESSION ON FULL COURSE ANTI-PD-1 Stage 3/4 Progressive Documented No intervening Eligible Melanoma Received at therapies permitted patient/definitiv least 12 weeks + disease + disease + o

  17. Slide 17: Patient Demographics and Disease Characteristics

    Patient Demographics and Disease Characteristics ‡Based on maximum value prior to dosing; #2 patients with ≥ 2X ULN Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 17

  18. Slide 18: 5 of 54 Evaluable Patients had 100% Tumor Reduction

    Investigator-Assessed Response per Recist v1.1 – Preliminary Data 5 of 54 Evaluable Patients had 100% Tumor Reduction Fernandez-Peñas, P. et al., SITC Annual Meeting 2020 data as of September, 2020 18

  19. Slide 19: Treatment-Related Adverse Events (TRAE) in ≥ 5% of Patients

    Treatment–Related Adverse Events (TRAE) in ≥ 5% of Patients All Grades n(%) (N=56) Grade 1/2 Grade 3 Grade 4 Grade 5 Patients with at least one TEAE 43 (76.8%) 40 (71.4%) 3 (5.4%) - - Fatigue 15 (26.8%) 15 (26.8%) - - - Procedural pain 13 (23.2%) 13 (23.2%) - - - Diarrhea 11 (19.6%) 11 (19.6%) - - -

  20. Slide 20: Treated and Untreated Lesions from Responding Patients

    Treated and Untreated Lesions from 16 Responding Patients Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 20

  21. Slide 21: Actively Progressing Patients & Short Interval Between Last Anti-PD-1 Dose and Study Treatment

    Actively Progressing Patients & Short Interval Between the Last Dose of Anti-PD-1 and Study Treatment Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, 21 Data as of September, 2020

  22. Slide 22: Actively Growing Lesions Significantly Reduced in Size after pIL-12 + Pembrolizumab

    Actively Growing Lesions Significantly Reduced in Size after pIL-12 + Pembrolizumab Treatment Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 22

  23. Slide 23: Pseudo Progression in Target Lesion followed by Tumor Response

    Pseudo Progression in Target Lesion followed by tumor Response [Stage IVB; PR (-93%)] Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 23

  24. Slide 24: Progression on Ipi/Nivo Followed by Tumor Response

    Progression on Ipi/Nivo Followed by Tumor Response[Stage IVC; PR (-53%)] Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 24

  25. Slide 25: US Market Opportunity

    US Market Focusing First on Metastatic Opportunity Melanoma in the United States 91,000 diagnosis 9,000 deaths each year each year 90% of all cancer cases are solid tumors Incidence of US melanoma market melanoma on the projected to almost 1.6M new cases of solid tumors in the US rise (1.4% yearly f

  26. Slide 26: The Field is Narrowing

    Technologies Currently Focused on Checkpoint Refractory Late-Stage Melanoma TAVO (IL-12) Toll-Like Receptor 9 • Recently failed Phase 3 study Single agent activity Abscopal effect (TLR9) • Remaining TLR9 agonist programs IT + EP Safety Agonists efficacy in question Fast Track & Orphan Tumor-Infiltra

  27. Slide 27: Commercialization by 2022 Targeted

    Commercialization by 2022 Targeted 2021 2022 Pre-BLA Meeting Projected FDA Accelerated with FDA Approval of TAVO for Metastatic Melanoma Potential US TAVO is US Orphan Designated Mid-2022 and Keynote-695 is fast Regulatory Planned submission of tracked. OncoSec will seek Timeline BLA for Accelerated

  28. Slide 28: Expanding KEYNOTE-890 into First-Line mTNBC

    Expanding KEYNOTE-890 into First-Line mTNBC Primary Endpoint: ORR by blinded independent central PHASE 2 COHORT 1 COHORT 2 review (BICR) based Multi-cohort, open-label study TAVO and KEYTRUDA on RECIST v1.1 TAVO and KEYTRUDA plus of TAVO in combination with in patients with heavily Chemotherapy in p

  29. Slide 29: Case #1: TNBC BOR: CR (-100.0%)

    CASE #1: TNBC BOR: CR (-100.0%) Total # Baseline Max tumor Age Sex Metastasis Prior Rx EOT of priors SLD (mm) reduction 35 F Liver, skin, LN 3 Paclitaxel; dox + cyclopho + goserelin; capecitabine 84.5 -100 Ongoing LDH at 1 non target skin nodule was treated with PD-L1 IL-12 EP. Three liver target le

  30. Slide 30: Case #2: TNBC BOR: PR (-67.0%)

    CASE #2: TNBC BOR: PR (-67.0%) Total # Baseline Max Tumor Age Sex Metastasis Prior Rx EOT of priors SLD (mm) reduction Breast, lung, lymph Paclitaxel: capecitabine: eribulin; 46 F 5 116 -67 Ongoing node cyclo + dox: carbo + gem LDH at PD-L1 Baseline Baseline C9D1 251 Negative Partial response 25 Com

  31. Slide 31: Recent Peer Reviewed Publications

    Recent Peer Reviewed Publications *Click thumbnails to access full articles TAVO + PEMBRO IN ANTICIPATED TAVO SINGLE AGENT ABSCOPAL EFFECT ANTI-PD-1 CHECKPOINT FAILURES 31

  32. Slide 32: Future Opportunities: TAVO is Tumor Agnostic

    FUTURE OPPORTUNITIES TAVO™ is Tumor Agnostic Renal Cell Ovarian Head/Neck Carcinoma Triple Negative Bladder Colorectal Giving life to the promise Pancreatic Breast of immunotherapies across cancer types HI Few cancers are highly infiltrated or “HOT” - most LYMPHOCYTES fall on a spectrum from warm (c

  33. Slide 33: The Power of TAVO for Visceral Lesions

    The Power of TAVO™ INTRODUCING THE for Visceral Lesions VLA: Visceral Lesion Applicator (liver, GI, lung) Pioneering technology Flexible catheter- Rigid trocar-based designed to target and based applicator applicator treat tumors located deep inside the body Lower voltage Apollo generator to be used

  34. Slide 34: VLA Highlights

    VLA Highlights 1 Rigid and catheter models: Used with bronchoscope, cystoscope, and trocar 2 Prototype successfully tested in large animal model: bone, pancreas, liver, lung, & bladder NEEDLE/ELECTRODES EXPANDED ENTERS THE ORGAN DRUG DELIVERY GENE ELECTROTRANSFER 1 2 3 34

  35. Slide 35: OncoSec Catheter VLA

    ONCOSEC CATHETER VLA A P P L I C A B L E I N D I C AT I O N S VISCERAL LESION APPLICATOR Lung Bladder GI Tract BRONCHOSCOPE CYSTOSCOPE ENDOSCOPE A P P L I C AT O R M E A S U R E M E N T S Electrode Width Electrode Length Injection Needle 4.5m 8mm 4mm m (+/- 0.5mm) (+/- 0.5mm) (+/- 1mm) May reduce le

  36. Slide 36: OncoSec Rigid VLA

    ONCOSEC RIGID VLA A P P L I C A B L E I N D I C AT I O N S VISCERAL LESION APPLICATOR Liver Bone Pancreas A P P L I C AT O R M E A S U R E M E N T S Electrode Width Electrode Length Injection Needle 4.5m 8mm 4mm m (+/- 0.5mm) (+/- 0.5mm) (+/- 1mm) May reduce length depending on application 4.5mm LIV

  37. Slide 37: Leveraging World Class Strategic Partnerships to Enhance Pipeline Value

    Leveraging World Class Strategic Partnerships to Enhance Pipeline Value We are partnering with Merck Our partnership with CGP Through our partnership with on several KEYNOTE clinical gives us the ability to develop Sirtex, we have access to top- programs to potentially and introduce our products to

  38. Slide 38: Strong Financial Position to Drive TAVO Development Forward

    Strong Financial Position to Drive TAVO™ Development Forward ~$54M ~39M Cash & Total Shares Equivalent as of Outstanding as of 4/30/21 April 2021 Cash into approx 3Q22 No Debt 38 38

  39. Slide 39: Important Milestones Planned for 2021 and 2022

    Important Milestones Planned for 2021 and 2022 • Filing of new IND for second product candidate combining IL-12 with CXCL9 • FDA clearance GenPulse, the planned go-to-market generator • Commencing Phase 3 clinical trial of TAVO + pembro in metastatic melanoma • KEYNOTE-890 data update presented at a

  40. Slide 40: OncoSec is Positioned for Success with TAVO

    OncoSec is Positioned Positive tumor Well tolerated, natural shrinkage/response data solution that may increase being generated by our lead the efficacy of checkpoint for Success product candidate, TAVO, across multiple solid tumor therapies with TAVO™ types Expanding device Fast Track and US Orphan

  41. Slide 41: Thank You

    Thank You HEADQUARTERS LAB & RESEARCH 24 NORTH MAIN STREET 3565 GENERAL ATOMICS CT. PENNINGTON, NJ SAN DIEGO, CA

OncoSec Medical — Investor Presentation (June 2021) on 6ix